EP3983412A4 - PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF - Google Patents

PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF Download PDF

Info

Publication number
EP3983412A4
EP3983412A4 EP20821692.9A EP20821692A EP3983412A4 EP 3983412 A4 EP3983412 A4 EP 3983412A4 EP 20821692 A EP20821692 A EP 20821692A EP 3983412 A4 EP3983412 A4 EP 3983412A4
Authority
EP
European Patent Office
Prior art keywords
prostaglandin
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20821692.9A
Other languages
German (de)
French (fr)
Other versions
EP3983412A1 (en
Inventor
Jiwen Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teon Therapeutics Inc
Original Assignee
Teon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teon Therapeutics Inc filed Critical Teon Therapeutics Inc
Publication of EP3983412A1 publication Critical patent/EP3983412A1/en
Publication of EP3983412A4 publication Critical patent/EP3983412A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20821692.9A 2019-06-11 2020-06-09 PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF Withdrawn EP3983412A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859924P 2019-06-11 2019-06-11
PCT/US2020/036852 WO2020251957A1 (en) 2019-06-11 2020-06-09 Prostaglandin e2 receptor 4 antagonists and uses thereof

Publications (2)

Publication Number Publication Date
EP3983412A1 EP3983412A1 (en) 2022-04-20
EP3983412A4 true EP3983412A4 (en) 2023-12-27

Family

ID=73781536

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20821692.9A Withdrawn EP3983412A4 (en) 2019-06-11 2020-06-09 PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF

Country Status (5)

Country Link
US (1) US20220324803A1 (en)
EP (1) EP3983412A4 (en)
JP (1) JP2022536607A (en)
CN (1) CN114206866A (en)
WO (1) WO2020251957A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143825A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2015094902A1 (en) * 2013-12-17 2015-06-25 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators
EP2422779B1 (en) * 2009-04-22 2016-01-06 RaQualia Pharma Inc. Selective ep4 receptor antagonistic substance for treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101284773A (en) * 2001-08-09 2008-10-15 小野药品工业株式会社 Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
ES2392192T3 (en) * 2006-04-24 2012-12-05 Merck Canada Inc. Indole amide derivatives as EP4 receptor antagonists
JP5408434B2 (en) * 2007-07-03 2014-02-05 アステラス製薬株式会社 Amide compounds
EP2565191B1 (en) * 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
JP5536773B2 (en) * 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Heterocyclic amide derivatives as EP4 receptor antagonists
WO2015188051A1 (en) * 2014-06-06 2015-12-10 Biogen Ma Inc. Atx modulating agents
WO2018195123A1 (en) * 2017-04-18 2018-10-25 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
CN111727044A (en) * 2018-02-05 2020-09-29 深圳市原力生命科学有限公司 Heterobicyclic Carboxylic Acids for the Treatment of Cancer or Inflammatory Diseases
US12240812B2 (en) * 2019-01-22 2025-03-04 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
CN112608271A (en) * 2020-11-26 2021-04-06 安润医药科技(苏州)有限公司 Amide derivatives and their use in the preparation of EP4 receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143825A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
EP2422779B1 (en) * 2009-04-22 2016-01-06 RaQualia Pharma Inc. Selective ep4 receptor antagonistic substance for treatment of cancer
WO2015094902A1 (en) * 2013-12-17 2015-06-25 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020251957A1 *

Also Published As

Publication number Publication date
US20220324803A1 (en) 2022-10-13
JP2022536607A (en) 2022-08-18
EP3983412A1 (en) 2022-04-20
WO2020251957A1 (en) 2020-12-17
CN114206866A (en) 2022-03-18

Similar Documents

Publication Publication Date Title
LT3762380T (en) PHENYLPYROLIDINONE FORMILPEPTIDO 2 RECEPTOR ANTAGONISTS
EP4054583A4 (en) MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF
IL292692A (en) mrgprx2 antagonists and their uses
EP3697759A4 (en) MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP3978528A4 (en) INTERLEUKIN-4 RECEPTOR ANTIBODIES AND THEIR USE
EP3860977A4 (en) INTEGRIN ANTAGONISTS
IL285626A (en) Claudin 6 antibodies and their uses
EP4081525C0 (en) Antagonists of the spirocyclic piperidine melanocortin subtype 2 receptor (MC2R) and their uses
EP3938401A4 (en) ANTI-BCMA CHEMICAL ANTIGEN RECEPTORS
EP3802500A4 (en) MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND THEIR USES
EP3703680A4 (en) MUSCARIN M4 ACETYLCHOLINE RECEPTOR ANTAGONISTS
EP3807318A4 (en) MULTI-SPECIFIC ANTIBODY CONSTRUCTIONS
EP4071172A4 (en) ANTI-LILRB1 ANTIBODIES AND USES THEREOF
EP3651762A4 (en) MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
IL292693A (en) mrgprx2 antagonists and their uses
EP3746421A4 (en) MUSCARIN ACETYLCHOLIN M4 RECEPTOR ANTAGONISTS
EP3823978A4 (en) ANTI-CRNF ANTIBODY COMPOSITIONS
MA54052A (en) ANTIBODY FORMULATION
IL286696A (en) Human anti-claudin 18.2 chimeric antigen receptors and uses thereof
MA53218A (en) INTEGRIN ANTAGONISTS
EP3654982A4 (en) 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
EP3723787A4 (en) DARIC INTERLEUKIN RECEPTORS
MA54139A (en) ANTIBODY FORMULATION
EP3894441A4 (en) RANK ANTAGONISTS AND THEIR USES
EP3762386A4 (en) ADENOSINE RECEPTOR ANTAGONISTS AND THEIR USES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073517

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230511

A4 Supplementary search report drawn up and despatched

Effective date: 20231124

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 209/42 20060101ALI20231120BHEP

Ipc: A61P 35/00 20060101ALI20231120BHEP

Ipc: A61K 31/4045 20060101ALI20231120BHEP

Ipc: A61K 31/416 20060101ALI20231120BHEP

Ipc: A61K 31/472 20060101ALI20231120BHEP

Ipc: A61K 31/437 20060101ALI20231120BHEP

Ipc: C07D 209/20 20060101ALI20231120BHEP

Ipc: C07D 231/56 20060101ALI20231120BHEP

Ipc: C07D 471/04 20060101AFI20231120BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240613